PLUVICTO Novartis Pharmaceuticals Australia Pty Ltd

Pluvicto (lutetium [177Lu] vipivotide tetraxetan) is proposed as a treatment for adults with advanced prostate cancer that has spread and no longer responds to hormone therapy. It is used in patients when the cancer shows a specific marker (called PSMA) and after patients have already been treated with hormone-blocking medicines and, in some cases, chemotherapy.